WS Bellevue Healthcare Fund

Please find a more detailed description of share classes here.

Investment Focus

ISIN-No. GB00BN0ZBH90

The investment objective is to provide Shareholders with capital growth and income over the long term, through investment in listed or quoted global healthcare companies.

Indexed performance (as at: 22.10.2021)

NAV: GBP 0.99 (22.10.2021)


Fonds (Brutto)
01 Jan 2010 - 01 Jan 2010
An error occurred - no data to display

Rolling performance (22.10.2021)

Acc-GBPBenchmark

Annualized performance (22.10.2021)

Acc-GBPBenchmark
1 yearn.a.n.a.
3 yearsn.a.n.a.
5 yearsn.a.n.a.
Since Inception p.a.n.a.n.a.

Cumulative performance (22.10.2021)

Acc-GBPBenchmark
1M0.74%n.a.
YTDn.a.n.a.
1 yearn.a.n.a.
3 yearsn.a.n.a.
5 yearsn.a.n.a.
Since Inception-0.93%n.a.

Annual performance

Acc-GBPBenchmark

Investment Focus

The investment objective is to provide Shareholders with capital growth and income over the long term, through investment in listed or quoted global healthcare companies.Show moreShow less

Investment suitability & Risk

Low risk

High risk

General Information

Investment ManagerBellevue Asset Management (UK) Ltd
CustodianCACEIS Bank, UK Branch
Fund AdministratorCACEIS Bank, UK Branch
AuditorGrant Thornton UK LLP
Launch date30.08.2021
Year end closing30. Nov
NAV CalculationDaily "Forward Pricing"
Cut of time17:00 UK time
Management Fee0.95%
ISIN numberGB00BN0ZBH90
BloombergWBHECGX LN
Total expense ratio (TER)1.15% (30.09.2021)

Legal Information

Legal formUK OEIC

Top 10 positions

Jazz Pharmaceuticals
Insmed Incorporated
Vertex Pharmaceut.
Anthem
Humana
Bristol-Myers
Option Care Health
UnitedHealth
Tandem Diabetes Care
Accolade
7.4%
6.2%
5.8%
5.8%
5.7%
4.9%
4.5%
4.3%
4.1%
3.8%

Market capitalization

0 - 1 bn
1 - 2 bn
2 - 5 bn
5 - 15 bn
15 - 20 bn
> 20 bn
Others
3.2%
6.3%
30.3%
18.1%
8.1%
26.3%
7.7%

Geographic breakdown

United States
China
Others
Cash
84.7%
1.5%
11.2%
2.6%

Breakdown by sector

Services
Biotechnology
Medtech
Healthcare Technology
Generics
Others
Cash
21.9%
20.8%
12.3%
8.7%
7.4%
26.2%
2.6%

Currency

USD
GBP
HKD
95.9%
2.6%
1.5%

Show moreShow less

  • Portfolio Manager

    Paul Major

    Paul Major has been serving as Portfolio Manager at Bellevue Asset Management (UK) Ltd since 2016. His previous roles include Research Partner at Redburn and Analyst at UBS Warburg. He holds a Master's degree in Biochemistry from the University of Bath, UK.
  • Portfolio Manager

    Brett Darke

    Brett Darke (joined 1 September 2017) has 11 years experience covering healthcare and the wider lifesciences sector on the buy-side at TT International, on both long-only and long/short funds. Brett previously worked for five years in corporate finance at Merrill Lynch and Bear Stearns. He holds a Masters degree in Medicine and Management studies from Cambridge University and is a CFA charterholder.
1